In a large cohort of the Chinese cancer population, the frequency of reversion mutations in pan-cancer unselected patients was 1.7%, with the most events reported in BRCA1, BRCA2, and PALB2 genes [2]. This evidence concerns the gene BRCA1 and cancer.